Benmelstobart Plus Anlotinib Is Unlikely to Be Cost-Effective for Advanced Renal Cell Carcinoma: An Integrated Disease Burden and Cost-Effectiveness Analysis

Kidney cancer (KC) is an important public-health challenge in China. Although benmelstobart plus anlotinib (BEN + AL) improves survival compared with sunitinib (SUN) for advanced renal cell carcinoma, its economic value in the Chinese healthcare system remains uncertain. Epidemiological trends in KC...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Haiyan Xu BSN, Liejiong Wang BS, Ying Lou MM, Zhaoqi Qiu BS, Feng Xuan BS
Formato:	Artigo
Idioma:	Inglês
Publicado em:	SAGE Publishing 2026-04-01
coleção:	Inquiry: The Journal of Health Care Organization, Provision, and Financing
Acesso em linha:	https://doi.org/10.1177/00469580261440346
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!